Sai Life Sciences share price
NSE: SAILIFEBSE: 544306Pharmaceuticals & BiotechnologySmall Cap
Sai Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2024 · Issue price ₹549
Last close ₹1,487.20up ₹1.00 (0.07%)BSE ₹1,486.80
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,486.20.
28 Oct: open ₹1,473.80, high ₹1,515.00, low ₹1,461.00
52-week range of traded prices to 28 Oct 2026
₹783.85Low, 5 Feb 2026₹1,697.00High, 9 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹31,591 Cr329th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 87.33
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 12.72
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 18.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,75,45047.3% delivered
About Sai Life Sciences
Sai Life Sciences is a contract research, development and manufacturing organisation (CRDMO) based in Hyderabad, India, working for pharmaceutical and biotechnology companies.1 It offers discovery, development and manufacturing for new small-molecule drugs, from early research to commercial supply, and is adding newer drug types such as peptides, antibody-drug conjugates and oligonucleotides.1 It has labs near clients in Greater Boston, US, and Manchester, UK, and research and manufacturing sites in India.2
Its integrated research campus is in Genome Valley, Hyderabad, and its manufacturing sites include Bollaram, Hyderabad, and Bidar, Karnataka.23 Its subsidiaries are Sai Life Sciences Inc in the US, Sai Life Sciences GmbH in Germany and Sai Life Pharma Private Limited in India, and it has branches in the UK and Japan.4
It was incorporated in 1999 and began as a medicinal chemistry partner (designing and making candidate drug molecules) to US biotechnology companies.5 In 2004 it acquired manufacturing capacity at Bollaram and Bidar.6 Its shares were listed on the NSE and BSE in December 2024.7
Ranga Raju Kanumuri, its chairman and whole-time director, and his son Krishnam Raju Kanumuri, its managing director and chief executive officer, are the company's promoter directors.89
Sai Life Sciences key points
Results
- In the quarter to Jun 2026, consolidated revenue was ₹554 crore, up 12% from a year earlier.1011
- In the quarter to Jun 2026, consolidated EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹148 crore, up 18% from a year earlier, and profit after tax was ₹73 crore, up 22%.1211
- In the year to Mar 2026, revenue was ₹2,192 crore, EBITDA ₹661 crore and profit after tax ₹349 crore.13
- In the year to Mar 2026, revenue grew 29%, EBITDA 56% and profit after tax 105% from the year before.14
Business segments
- CDMO (contract development and manufacturing). Develops manufacturing processes and supplies drug ingredients from clinical trials to commercial sale. CDMO revenue was ₹1,417 crore in the year to Mar 2026, 65% of the total and up 33%.1516
- CRO (contract research, discovery services). Drug discovery research for clients, including chemistry, biology, DMPK (how the body absorbs and clears a drug) and toxicology. CRO revenue was ₹775 crore in the year to Mar 2026, 35% of the total and up 24%.1718
- In the quarter to Jun 2026, CDMO gave about 60% of revenue and CRO 40%, and CDMO revenue grew around 6% from a year earlier.19
Molecule pipeline
- In the quarter to Jun 2026, the company's CDMO pipeline held 33 active commercial molecules (medicines on sale for which it supplies material) and 14 late-phase molecules.10
- On its call of 7 Aug 2026, the company said it had added 6 late-phase molecules over the previous 15 months, 5 of them from large pharmaceutical clients on full-time-equivalent (FTE) contracts, which pay for a dedicated team.19
- In calendar 2025 the company took part in the discovery, development or commercial manufacturing of 5 molecules approved by the US Food and Drug Administration, and it has supported 17 drug launches over the past 5 years.20
Plants and capacity
- The Bidar site has 700 KL (kilolitres of reactor volume) of capacity under cGMP, the manufacturing rules drug regulators enforce, and serves the US, UK, EU and Japan. The company's manufacturing has 80 production trains (sets of linked reactors and equipment).2122
- As of Mar 2026, the company was developing a new manufacturing site at Choutuppal, planned across about 40 acres and designed for around 1,400 KL of reactor capacity.23
Customers and partners
- The company has more than 300 active customers across the US, UK, EU and Japan, including 19 of the 25 largest pharmaceutical companies by market value in 2025.24
- Global large pharmaceutical customers gave 49% of revenue in the year to Mar 2026, and 2 more large pharmaceutical customers qualified the company for commercial supply during the year.25
- Returning customers gave over 90% of revenue in the year to Mar 2026, as in the year before.20
- Customer base by business, pharmaceutical against biotech companies26
Item year to Mar 2026 CDMO, pharma 94% CDMO, biotech 6% CRO, pharma 48% CRO, biotech 52%
Expansion and capital spending
- Capital expenditure was ₹633 crore in the year to Mar 2026 and ₹263 crore in the quarter to Jun 2026.2527
- The company stated in its annual report for the year to Mar 2026 that it plans capital spending of ₹1,100 to ₹1,300 crore in the year to Mar 2027, 75% for capacity expansion and 25% for capability, technology and AI.28
- On its earnings call of 7 Aug 2026, the company said the first of 2 production blocks of 225 KL each at Bidar, 450 KL in all, would come on stream, with the plants ready in the second half of the year to Mar 2027.29
- On its earnings call of 7 Aug 2026, the company said it plans to break ground on a peptide (short chain of amino acids) manufacturing facility at its new site on undeveloped land (a greenfield site) near Hyderabad, expected to be operational in 2028.30
What the company expects
Recent events
- On 26 Feb 2026, ICRA assigned AA (Stable) to ₹550.00 crore of long-term fund-based facilities and A1+ to ₹218.60 crore of short-term non-fund-based facilities, ₹768.60 crore in all; a credit rating is an agency's opinion of how likely a borrower is to repay.33
- On 27 Oct 2025, the company broke ground on a new Process R&D Center, where it works out how to make clients' drugs at scale, at its Hyderabad campus; it said the centre would double its Process R&D capacity.34
Last updated
All 34 sources, each with its page
- 1. Annual report, 25 Aug 2026, page 7
- 2. Investor presentation, 7 Aug 2026, page 15
- 3. Annual report, 25 Aug 2026, page 340
- 4. Annual report, 25 Aug 2026, page 47
- 5. Investor presentation, 7 Aug 2026, page 14
- 6. Annual report, 25 Aug 2026, page 11
- 7. Investor presentation, 7 Aug 2026, page 13
- 8. Annual report, 25 Aug 2026, page 164
- 9. Annual report, 25 Aug 2026, page 150
- 10. Investor presentation, 7 Aug 2026, page 5
- 11. Investor presentation, 7 Aug 2026, page 8
- 12. Investor presentation, 7 Aug 2026, page 7
- 13. Annual report, 25 Aug 2026, page 26
- 14. Annual report, 25 Aug 2026, page 14
- 15. Annual report, 25 Aug 2026, page 137
- 16. Annual report, 25 Aug 2026, page 14
- 17. Annual report, 25 Aug 2026, page 137
- 18. Annual report, 25 Aug 2026, page 14
- 19. Earnings call, 7 Aug 2026, page 6
- 20. Earnings call, 7 Aug 2026, page 7
- 21. Investor presentation, 7 Aug 2026, page 15
- 22. Investor presentation, 7 Aug 2026, page 17
- 23. Annual report, 25 Aug 2026, page 55
- 24. Investor presentation, 7 Aug 2026, page 13
- 25. Annual report, 25 Aug 2026, page 137
- 26. Annual report, 25 Aug 2026, page 26
- 27. Investor presentation, 7 Aug 2026, page 7
- 28. Annual report, 25 Aug 2026, page 14
- 29. Earnings call, 7 Aug 2026, page 12
- 30. Earnings call, 7 Aug 2026, page 4
- 31. Earnings call, 7 Aug 2026, page 7
- 32. Earnings call, 7 Aug 2026, page 14
- 33. Exchange filing, 26 Feb 2026, page 2
- 34. Exchange filing, 27 Oct 2025, page 2
Results
Consolidated; ₹ crore.Sai Life Sciences quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹554 Crdown 7.95%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹73 Crdown 29.69%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 13.2%
Revenue by quarter
Peak revenue ₹602 Cr, quarter to Mar 2026; lowest ₹440 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Net profit | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| Net margin | 12.2% | 15.2% | 12.2% | 15.6% | 18.0% | 17.3% | 13.2% |
Consolidated. The 7 quarters from Dec 2024, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,192 Crup 29.38%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹349 Crup 105.08%
- Net margin
- 15.9%
Revenue by year
Peak revenue ₹2,192 Cr, year to Mar 2026; lowest ₹1,695 Cr, year to Mar 2025
Net profit by year, a loss in red
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 1,695 | 2,192 |
| Net profit | 170 | 349 |
| Net margin | 10.0% | 15.9% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Contract Research, Development and Manufacturing (CRDMO), which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Sai Life Sciences PE ratio and valuation
Price to earnings
At or below today's level on 88% of 241 trading days over the last year.
LowestHighest
Its median68.66Industry median27.98
Price to book
At or below today's level on 89% of 247 trading days over the last year.
LowestHighest
Its median9.65Industry median2.94
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +27.8% | +101.8% | −36.7% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
175 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 64 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 175 funds holding Sai Life Sciences
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 7
- AddedAdded. Funds that held more shares than at the end of the month before.
- 34
- CutCut. Funds that held fewer shares than at the end of the month before.
- 59
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 74
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 65,63,832 | 1.24% | ₹1,000.7 Cr |
 Invesco India Small Cap FundInvesco Mutual Fund | 54,40,617 | 5.14% | ₹829.4 Cr |
| Invesco India Large & Mid Cap FundInvesco Mutual Fund | 42,83,799 | 5.36% | ₹653.1 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 39,68,891 | 1.13% | ₹605.1 Cr |
 Axis Small Cap FundAxis Mutual Fund | 37,02,004 | 1.84% | ₹564.4 Cr |
| Invesco India Mid Cap FundInvesco Mutual Fund | 34,16,927 | 3.31% | ₹520.9 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 26,79,487 | 2.21% | ₹408.5 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 23,55,745 | 3.92% | ₹359.1 Cr |
 DSP Healthcare FundDSP Mutual Fund | 16,02,712 | 6.52% | ₹244.3 Cr |
 Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 12,63,192 | 3.15% | ₹192.6 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Sai Life Sciences insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 8 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Sai Life Sciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Sai Life Sciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 IPCA LaboratoriesIPCALAB | 48,978 | 37.39 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 43,233 | 38.10 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 WockhardtWOCKPHARMA | 31,091 | 76.02 | 6.29 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 30,994 | – | 3.81 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 Acutaas ChemicalsACUTAAS | 30,374 | 69.17 | 16.35 | +45.2% | +96.1% | 26.9% | 30.2% | 0.07% |
 Rubicon ResearchRUBICON | 25,889 | 89.83 | 20.09 | – | – | 22.4% | 25.8% | 0.10% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Sai Life Sciences announcements
Oct 2026
19 Oct · Analysts
12 Oct · Disclosure
Sep 2026
17 Sep · Meeting
Sai Life Sciences share price by year
Each calendar year to 2025.Sai Life Sciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 908.40 | +20.9% | 925.90 | 640.25 |
| 2024 | 751.20 | – | 764.65 | 703.65 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 18 Dec 2024.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,441.00 | 1,490.30 | 1,435.40 | 1,486.20 | 1,476.12 | 2,30,944 | 48.7% |
| 26 Oct 2026 | 1,380.00 | 1,450.00 | 1,375.00 | 1,445.30 | 1,424.04 | 2,80,136 | 45.9% |
| 23 Oct 2026 | 1,391.90 | 1,429.00 | 1,382.90 | 1,395.30 | 1,402.51 | 6,69,411 | 47.5% |
| 22 Oct 2026 | 1,390.00 | 1,407.80 | 1,371.00 | 1,395.90 | 1,393.29 | 1,76,826 | 46.0% |
| 21 Oct 2026 | 1,395.00 | 1,399.10 | 1,360.60 | 1,393.60 | 1,380.63 | 4,27,119 | 49.7% |
| 19 Oct 2026 | 1,381.00 | 1,412.60 | 1,370.40 | 1,395.90 | 1,393.76 | 2,90,389 | 52.2% |
| 16 Oct 2026 | 1,400.00 | 1,403.30 | 1,371.40 | 1,389.40 | 1,389.08 | 6,39,029 | 57.5% |
| 15 Oct 2026 | 1,432.00 | 1,444.70 | 1,390.00 | 1,394.70 | 1,407.88 | 6,31,706 | 65.2% |
| 14 Oct 2026 | 1,456.50 | 1,456.60 | 1,421.30 | 1,432.10 | 1,434.67 | 4,06,225 | 61.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- SAILIFE
- BSE code
- 544306
- ISIN
- INE570L01029
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.sailife.com
- CIN
- L24110TG1999PLC030970
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1999
- Registered office
- Plot No. DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal Medchal-Malkajgiri District, Hyderabad 500078, Telangana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap